The Importance of Diagnosing Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP) Based on the Defined Criteria

  • Pedro Weslley RosarioEmail author
Endocrine Tumors

Dear Editor

We read with great interest the study by Eskander et al.1 published in Annals of Surgical Oncology. The controversy addressed and the number of patients included make the importance of the study indisputable. However, in view of the unexpected results that differ from most previous series, and of the impact they may have on the actual concept of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) as an indolent neoplasm, we would like to express some concern about the methodology of the study and a certain divergence with its conclusions.

The criteria for the diagnosis of NIFTP are well established.2Making the retrospective diagnosis based only on the information provided in the original pathology report, without at least reviewing the slides in order to actively identify the findings that constitute the diagnostic criteria, does not seem to be possible. This analysis (retrospective and based only on the original report) becomes even more...



Pedro Weslley Rosario declares he has no conflicts of interest.


This research did not receive any specific grants from any funding agencies in the public, commercial, or not-for-profit sector.


This study was approved by the Research Ethics Committee of our institution.


  1. 1.
    Eskander A, Hall SF, Manduch M, Griffiths R, Irish JC. A population-based study on NIFTP incidence and survival: is NIFTP really a “benign” disease? Ann Surg Oncol. 2019;26(5):1376–84.CrossRefGoogle Scholar
  2. 2.
    Nikiforov YE, Baloch ZW, Hodak SP, Giordano TJ, Lloyd RV, Seethala RR, et al. Change in diagnostic criteria for noninvasive follicular thyroid neoplasm with papillary like nuclear features. JAMA Oncol. 2018;4:1125–26.CrossRefGoogle Scholar
  3. 3.
    Kim MJ, Won JK, Jung KC, Kim JH, Cho SW, Park DJ, et al. Clinical characteristics of subtypes of follicular variant papillary thyroid carcinoma. Thyroid 2018; 28:311–18.CrossRefGoogle Scholar
  4. 4.
    Baloch ZW, Harrell RM, Brett EM, Randolph G, Garber JR; AACE Endocrine Surgery Scientific Committee and Thyroid Scientific Committee. American Association of Clinical Endocrinologists and American College of Endocrinology disease state commentary: managing thyroid tumors diagnosed as noninvasive follicular thyroid neoplasm with papillary-like nuclear features. Endocr Pract. 2017;23:1150–55.CrossRefGoogle Scholar
  5. 5.
    Ferris RL, Nikiforov Y, Terris D, Seethala RR, Ridge JA, Angelos P, et al. AHNS series: do you know your guidelines? AHNS endocrine section consensus statement: state-of-the-art thyroid surgical recommendations in the era of noninvasive follicular thyroid neoplasm with papillary-like nuclear features. Head Neck. 2018;40:1881–88.CrossRefGoogle Scholar
  6. 6.
    Cho U, Mete O, Kim MH, Bae JS, Jung CK. Molecular correlates and rate of lymph node metastasis of non-invasive follicular thyroid neoplasm with papillary-like nuclear features and invasive follicular variant papillary thyroid carcinoma: the impact of rigid criteria to distinguish noninvasive follicular thyroid neoplasm with papillary-like nuclear features. Mod Pathol. 2017;30:810–25.CrossRefGoogle Scholar
  7. 7.
    Aburjania Z, Jang S, Montemayor-Garcia C, et al. Encapsulated follicular variant of papillary thyroid cancer: are these tumors really benign? J Surg Res. 2017;216:138–42.CrossRefGoogle Scholar
  8. 8.
    Parente DN, Kluijfhout WP, Bongers PJ, et al. Clinical safety of renaming encapsulated follicular variant of papillary thyroid carcinoma: is NIFTP truly benign? World J Surg. 2018;42:321–26.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  1. 1.Instituto de Ensino e Pesquisa da Santa Casa de Belo HorizonteBelo HorizonteBrazil

Personalised recommendations